Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy

Frontiers in Oncology

Oncology

Meredith A. Morgan¹  Qiang Zhang¹  Victoria Valvo²  Emanuele Vitale³  Marco Tigano⁴  Rachel Evans⁵ 

[1] Department of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States;Department of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States;Cancer Biology Program, University of Michigan, Ann Arbor, MI, United States;Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy;MitoCare Center, Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA, United States;MitoCare Center, Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA, United States;Richard Dimbleby Department of Cancer Research, Randall Division & Division of Cancer Studies, Kings College London, London, United Kingdom;Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom;

关键词: radiotherapy;    DNA damage response;    immunotherapy;    innate immunity;    tumor microenvironment;   

DOI  :  10.3389/fonc.2023.1257622

 received in 2023-07-12, accepted in 2023-07-17,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Valvo, Vitale, Tigano, Evans, Morgan and Zhang